Overview

The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy

Status:
Recruiting

Trial end date:
2024-08-30

Target enrollment:

Participant gender:

Summary

The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung cancer who failed to standard therapy.

Phase:

Phase 1

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Collaborators:

Asan Medical Center
Samsung Medical Center
Seoul National University Hospital